Ligand Pharmaceuticals
LGND
LGND
385 hedge funds and large institutions have $6.66B invested in Ligand Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 101 increasing their positions, 168 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
385
Holders Change
+39
Holders Change %
+11.27%
% of All Funds
8.82%
Holding in Top 10
10
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-23.08%
% of All Funds
0.23%
New
65
Increased
101
Reduced
168
Closed
22
Calls
$59.9M
Puts
$28.8M
Net Calls
+$31.1M
Net Calls Change
+$23M
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$63.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$40.4M |
| 3 |
Millennium Management
New York
|
+$26.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.4M |
| 5 |
BlackRock
New York
|
+$22.4M |
Top Sellers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$98.9M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$49.2M |
| 3 |
Goldman Sachs
New York
|
-$39.7M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$33.2M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
-$29.3M |
